Heinrich Schmidt Gayk

Summary

Country: Germany

Publications

  1. ncbi request reprint Performance evaluation of automated assays for beta-CrossLaps, N-MID-Osteocalcin and intact parathyroid hormone (BIOROSE Multicenter Study)
    Heinrich Schmidt-Gayk
    Department of Endocrinology and Oncology, Limbach Laboratory, Im Breitspiel 15, 69126 Heidelberg, Germany
    Clin Chem Lab Med 42:90-5. 2004
  2. ncbi request reprint New assays for intact parathyroid hormone and their clinical relevance for the diagnosis of hyperparathyroidism
    Heinz Jürgen Roth
    Clin Lab 48:589-93. 2002
  3. ncbi request reprint Influence of PTH assay methodology on differential diagnosis of renal bone disease
    Helmut Reichel
    Nephrological Center Villingen Schwenningen, Laboratory Group Limbach, Heidelberg, Germany
    Nephrol Dial Transplant 18:759-68. 2003
  4. ncbi request reprint Markers of bone resorption--measurement in serum, plasma or urine?
    Florian Huber
    University of Heidelberg, Germany
    Clin Lab 49:203-7. 2003
  5. ncbi request reprint Evaluation of serum beta-carboxy-terminal cross-linking telopeptide of type I collagen as marker of bone resorption in chronic hemodialysis patients
    Helmut Reichel
    Nephrological Center, Villingen Schwenningen, Germany
    Nephron Clin Pract 98:c112-8. 2004
  6. ncbi request reprint Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover
    Arja Nenonen
    Rheumatism Foundation Hospital, Heinola, and Department of Clinical Chemistry, University Hospital of Tampere, Finland
    J Bone Miner Res 20:1804-12. 2005
  7. ncbi request reprint Influence of the sample matrix on the stability of beta-CTX at room temperature for 24 and 48 hours
    Giuseppe Lippi
    Sezione di Chimica Clinica, Dipartimento di Scienze Morfologico Biomediche, Universita degli Studi di Verona, Italy
    Clin Lab 53:455-9. 2007
  8. ncbi request reprint The effect of B-vitamins on biochemical bone turnover markers and bone mineral density in osteoporotic patients: a 1-year double blind placebo controlled trial
    Markus Herrmann
    ANZAC Research Institute, University of Sydney, Sydney NSW, Australia
    Clin Chem Lab Med 45:1785-92. 2007
  9. doi request reprint Use of cinacalcet HCl to achieve the recommended targets of bone metabolism in a patient with therapy-resistant renal hyperparathyroidism
    Udo Bahner
    KfH Nierenzentrum Wuerzburg, Dialysis Unit, Wurzburg, Germany
    J Ren Nutr 18:383-8. 2008

Collaborators

Detail Information

Publications9

  1. ncbi request reprint Performance evaluation of automated assays for beta-CrossLaps, N-MID-Osteocalcin and intact parathyroid hormone (BIOROSE Multicenter Study)
    Heinrich Schmidt-Gayk
    Department of Endocrinology and Oncology, Limbach Laboratory, Im Breitspiel 15, 69126 Heidelberg, Germany
    Clin Chem Lab Med 42:90-5. 2004
    ..This has been shown in several external quality assessment schemes (EQAS)...
  2. ncbi request reprint New assays for intact parathyroid hormone and their clinical relevance for the diagnosis of hyperparathyroidism
    Heinz Jürgen Roth
    Clin Lab 48:589-93. 2002
  3. ncbi request reprint Influence of PTH assay methodology on differential diagnosis of renal bone disease
    Helmut Reichel
    Nephrological Center Villingen Schwenningen, Laboratory Group Limbach, Heidelberg, Germany
    Nephrol Dial Transplant 18:759-68. 2003
    ..Recently, a new PTH assay ('whole PTH') using an antibody directed specifically against PTH(1-4) has been introduced. It was the aim of the current study to evaluate whole PTH and parameters derived from whole PTH in renal bone disease...
  4. ncbi request reprint Markers of bone resorption--measurement in serum, plasma or urine?
    Florian Huber
    University of Heidelberg, Germany
    Clin Lab 49:203-7. 2003
    ....
  5. ncbi request reprint Evaluation of serum beta-carboxy-terminal cross-linking telopeptide of type I collagen as marker of bone resorption in chronic hemodialysis patients
    Helmut Reichel
    Nephrological Center, Villingen Schwenningen, Germany
    Nephron Clin Pract 98:c112-8. 2004
    ..beta-CTX is known to undergo a diurnal rhythm in normal individuals and to accumulate in chronic renal failure. beta-CTX has a potential role in noninvasive diagnosis of renal bone disease...
  6. ncbi request reprint Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover
    Arja Nenonen
    Rheumatism Foundation Hospital, Heinola, and Department of Clinical Chemistry, University Hospital of Tampere, Finland
    J Bone Miner Res 20:1804-12. 2005
    ..TRACP 5b had higher clinical sensitivity, area under the ROC curve, and signal-to-noise ratio than the other markers...
  7. ncbi request reprint Influence of the sample matrix on the stability of beta-CTX at room temperature for 24 and 48 hours
    Giuseppe Lippi
    Sezione di Chimica Clinica, Dipartimento di Scienze Morfologico Biomediche, Universita degli Studi di Verona, Italy
    Clin Lab 53:455-9. 2007
    ..In conclusion, the results of our investigation demonstrate that EDTA plasma is the most suitable sample matrix for the storage of beta-CTX at room temperature after centrifugation...
  8. ncbi request reprint The effect of B-vitamins on biochemical bone turnover markers and bone mineral density in osteoporotic patients: a 1-year double blind placebo controlled trial
    Markus Herrmann
    ANZAC Research Institute, University of Sydney, Sydney NSW, Australia
    Clin Chem Lab Med 45:1785-92. 2007
    ..Hyperhomocysteinemia is a new risk factor for osteoporosis. This study analyzed the effect of a homocysteine (HCY)-lowering treatment in osteoporotic individuals...
  9. doi request reprint Use of cinacalcet HCl to achieve the recommended targets of bone metabolism in a patient with therapy-resistant renal hyperparathyroidism
    Udo Bahner
    KfH Nierenzentrum Wuerzburg, Dialysis Unit, Wurzburg, Germany
    J Ren Nutr 18:383-8. 2008
    ....